blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3916095

EP3916095 - ANTISENSE COMPOUNDS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.06.2022
Database last updated on 11.09.2024
FormerThe application has been published
Status updated on  29.10.2021
Most recent event   Tooltip13.09.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
[2021/48]
Inventor(s)01 / SWAYZE, Eric E.
Carlsbad, California 92009 / US
 [2021/48]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2021/48]
Application number, filing date21155022.318.10.2007
[2021/48]
Priority number, dateUS200685289406P18.10.2006         Original published format: US 85289406 P
[2021/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3916095
Date:01.12.2021
Language:EN
[2021/48]
Search report(s)(Supplementary) European search report - dispatched on:EP03.11.2021
ClassificationIPC:C12N15/113, A61K31/712
[2021/48]
CPC:
A61K31/712 (EP,US); A61K31/7125 (EP,US); A61P43/00 (EP);
C12N15/111 (EP,US); C12N15/113 (EP,US); C12N2310/11 (EP,US);
C12N2310/315 (EP,US); C12N2310/321 (EP,US); C12N2310/3231 (EP,US);
C12N2310/3341 (EP,US); C12N2310/341 (EP,US); C12N2310/346 (EP,US);
C12N2310/351 (EP,US); C12N2320/53 (EP,US) (-)
C-Set:
C12N2310/321, C12N2310/3525 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2022/27]
Former [2021/48]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:ANTISENSE-VERBINDUNGEN[2021/48]
English:ANTISENSE COMPOUNDS[2021/48]
French:COMPOSÉS ANTISENS[2021/48]
Examination procedure31.05.2022Examination requested  [2022/27]
31.05.2022Date on which the examining division has become responsible
24.06.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
31.08.2022Amendment by applicant (claims and/or description)
Parent application(s)   TooltipEP07844422.1  / EP2092065
EP11186203.3  / EP2410054
EP16205317.7  / EP3202905
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
31.08.2022Request for further processing filed
31.08.2022Full payment received (date of receipt of payment)
Request granted
09.09.2022Decision despatched
Fees paidRenewal fee
03.02.2021Renewal fee patent year 03
03.02.2021Renewal fee patent year 04
03.02.2021Renewal fee patent year 05
03.02.2021Renewal fee patent year 06
03.02.2021Renewal fee patent year 07
03.02.2021Renewal fee patent year 08
03.02.2021Renewal fee patent year 09
03.02.2021Renewal fee patent year 10
03.02.2021Renewal fee patent year 11
03.02.2021Renewal fee patent year 12
03.02.2021Renewal fee patent year 13
03.02.2021Renewal fee patent year 14
29.09.2021Renewal fee patent year 15
15.09.2022Renewal fee patent year 16
13.09.2023Renewal fee patent year 17
12.09.2024Renewal fee patent year 18
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2004069991  (SANTARIS PHARMA AS [DK], et al) [A] 1-12 * the whole document *;
 [A]WO2005023825  (ISIS PHARMACEUTICALS INC [US], et al) [A] 1-12 * claims 1-3 *;
 [A]US2005153921  (MONIA BRETT P [US], et al) [A] 1-12 * the whole document *;
 [L]WO2012109395  (ISIS PHARMACEUTICALS INC [US], et al) [L] 1-12* the whole document *;
 [I]  - FLUITER K ET AL, "ON THE IN VITRO AND IN VIVO PROPERTIES OF FOUR LOCKED NUCLEIC ACID NUCLEOTIDES INCORPORATED INTO AN ANTI-H-RAS ANTISENSE OLIGONUCLEOTIDE", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, (20050606), vol. 6, no. 6, ISSN 1439-4227, pages 1104 - 1109, XP009069506 [I] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1002/cbic.200400419
 [A]  - W. F. LIMA ET AL, "The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis", MOLECULAR PHARMACOLOGY, US, (20061006), vol. 71, no. 1, doi:10.1124/mol.106.025429, ISSN 0026-895X, pages 73 - 82, XP055225537 [A] 1-12 * figure 2 *

DOI:   http://dx.doi.org/10.1124/mol.106.025429
by applicantUS4981957
 US5118800
 WO9324510
 US5319080
 WO9414226
 US5359044
 WO9426764
 US5393878
 US5446137
 US5466786
 US5514785
 US5519134
 US5567811
 US5576427
 US5591722
 US5597909
 US5610300
 US5627053
 US5639873
 US5646265
 US5658873
 US5670633
 US5700920
 US5792747
 WO9839352
 WO9914226
 US6268490
 US6525191
 US2003082807
 US6600032
 US2003207841
 US6670461
 US2004014959
 US2004143114
 US6770748
 US2004171570
 US6794499
 US2004219565
 WO2005021570
 WO2005121371
 US7034133
 US7053207
 WO2007090071
    - BELIKOVA et al., Tet. Lett., (19670000), vol. 37, pages 3557 - 3562
    - ZAMECNIK et al., Proc. Natl. Acad. Sci. U.S.A., (19780000), vol. 75, pages 280 - 284
    - MANOHARAN et al., Bioorg. Med. Chem. Lett., (19940000), vol. 4, page 1053
    - KABANOV et al., FEBS Lett., (19900000), vol. 259, page 327
    - LETSINGER et al., "86", Proc. Natl. Acad. Sci. USA, (19890000), page 6553
    - BERGER et al., Nuc Acid Res, (20000000), vol. 28, pages 2911 - 14
    - ALBAEK et al., J. Org. Chem., (20060000), vol. 71, pages 7731 - 7740
    - FLUITER et al., Chembiochem, (20050000), vol. 6, pages 1104 - 1109
    - SINGH et al., "4", Chem. Commun., (19980000), pages 455 - 456
    - KOSHKIN et al., Tetrahedron, (19980000), vol. 54, pages 3607 - 3630
    - WAHLESTEDT et al., Proc. Natl. Acad. Sci. U. S. A., (20000000), vol. 97, pages 5633 - 5638
    - KUMAR et al., Bioorg. Med. Chem. Lett., (19980000), vol. 8, pages 2219 - 2222
    - SINGH et al., J. Org. Chem., (19980000), vol. 63, pages 10035 - 10039
    - ELAYADI et al., "2", Curr. Opinion Invens. Drugs, (20010000), pages 558 - 561
    - BRAASCH et al., Chem. Biol., (20010000), vol. 8, pages 1 - 7
    - ORUM et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, pages 239 - 243
    - SINGH et al., Chem. Commun., (19980000), vol. 4, pages 455 - 456
    - MORITA et al., Bioorganic Medicinal Chemistry, (20030000), vol. 11, pages 2211 - 2226
    - FRIEDEN et al., Nucleic Acids Research, (20030000), vol. 21, pages 6365 - 6372
    - MANOHARAN et al., Ann. N.Y. Acad. Sci., (19920000), vol. 660, page 306
    - MANOHARAN et al., Bioorg. Med. Chem. Let., (19930000), vol. 3, page 2765
    - OBERHAUSER et al., "20", Nucl. Acids Res., (19920000), page 533
    - SAISON-BEHMOARAS et al., EMBO J., (19910000), vol. 10, page 111
    - SVINARCHUK et al., Biochimie, (19930000), vol. 75, page 49
    - MANOHARAN et al., Tetrahedron Lett., (19950000), vol. 36, page 3651
    - SHEA et al., Nucl. Acids Res., (19900000), vol. 18, page 3777
    - MANOHARAN et al., Nucleosides & Nucleotides, (19950000), vol. 14, page 969
    - MISHRA et al., Biochim. Biophys. Acta, (19950000), vol. 1264, page 229
    - CROOKE et al., J. Pharmacol. Exp. Ther., (19960000), vol. 277, page 923
    - FREIER et al., Nucleic Acids Research, (19970000), vol. 25, no. 22, pages 4429 - 4443
    - SCARINGE, Methods, (20010000), vol. 23, pages 206 - 217
    - GAIT et al., Applications of Chemically synthesized RNA in RNA: Protein Interactions, (19980000), vol. 1-36
    - GALLO et al., Tetrahedron, (20010000), vol. 57, pages 5707 - 5713
    - "Genbank", Database accession no. U92437.1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.